NCT00312663已完成1 期
A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS01B Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States
U.S. Army Medical Research and Development Command2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2006年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Safety - Most Frequently Reported Adverse Events and Grade
研究概览
简要总结
Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.
详细描述
- Controlled challenge, Phase I/IIa WRAIR study.
- Healthy, malaria-naive adults aged 18 - 50 years.
- 2 groups, 5 subjects in group A (10µg dose) and 13 subjects in group B(50µg dose).
- Control: none for immunization phase; infectivity controls for challenge and rechallenge phases. Six infectivity controls per day of challenge will be enrolled for the challenge phases, with 3 alternates available for challenge if needed.
- Vaccination schedule of 0, 1 months.
- Challenge of up to 13 subjects in Group B.
- Contingent upon short term efficacy, rechallenge of initially protected subjects 6 months (+/- 2 months) after second dose of vaccine.
- Self-contained study.
- Duration of the study, per subject: approximately 15 months (screening, enrollment, vaccination, challenge and rechallenge).
- Data collection will be by done onsite.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A male or non-pregnant female 18 to 50 years of age (inclusive) at the time of screening.
- •Written informed consent obtained from the subject before screening procedures.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.*
- •Available to participate for duration of study (approximately 15 months).
- •If the subject is female, she must be currently using birth control, must be surgically sterilized, or must be at least 1-year post menopausal.
- •Pass a comprehension assessment test.
排除标准
- •Prior receipt of an investigational malaria vaccine.
- •Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 28 days preceding the first dose of study vaccine, or planned use during the study period.
- •Administration of chronic immunosuppressants or other immune modifying drugs within six months of vaccination.
- •Chronic use of antibiotics with anti-malarial effects.
- •Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s).
- •History of use of anti-malarial medication within 60 days prior to vaccination.
- •Any history of malaria.
- •Known exposure to malaria within the previous 12 months.
- •Planned travel to malarious areas during the study period.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection.
- •A family history of congenital or hereditary immunodeficiency.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •Chronic or active neurologic disease including seizures, but not including a single febrile seizure as a child.
- •History of splenectomy.
- •Acute disease at the time of enrollment.
- •Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- •Personal history of autoimmune disease or subjects who describe a first-degree relative with clearly documented autoimmune disease.
- •Seropositive for hepatitis B surface antigen.
- •Seropositive for Hepatitis C virus (antibodies to HCV).
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned. administration during the study period
- •Pregnant or lactating female.
- •Suspected or known current alcohol abuse as defined by the American Psychiatric Association in DSM IV.
- •Chronic or active intravenous drug use.
- •History of severe reactions to mosquito bites as defined as anaphylaxis.
- •Female who intends to become pregnant during the study.
- •Any history of anaphylaxis in reaction to vaccination.
- •A clinical history of sickle cell disease or sickle cell trait.
- •Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.
研究组 & 干预措施
10ug dose FMP011
Experimental
Falciparum Malaria Protein 11 with AS01B adjuvant
干预措施: Falciparum Malaria Protein 11 with AS01B adjuvant. (Biological)
50ug dose FMP011
Experimental
Falciparum Malaria Protein 11 with AS01B adjuvant
干预措施: Falciparum Malaria Protein 11 with AS01B adjuvant. (Biological)
结局指标
主要结局
Safety - Most Frequently Reported Adverse Events and Grade
时间窗: 30 days post vaccination
An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to the study drug or clinically significant. Grade 1: Mild Grade 2: Moderate Grade 3: Severe
次要结局
- Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84(Days 0, 28, 42, and 84)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of AmericaPlasmodium Falciparum MalariaMalariaNCT00312702U.S. Army Medical Research and Development Command18
已完成
1 期
Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two AdjuvantsMalaria, VivaxNCT01081847Malaria Vaccine and Drug Development Center40
已完成
1 期
Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1Malaria, VivaxNCT04201431University of Oxford24
已完成
1 期
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium FalciparumMalariaNCT00487916National Institute of Allergy and Infectious Diseases (NIAID)150
已完成
1 期
Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)Healthy VolunteerHVNCT00340574National Institute of Allergy and Infectious Diseases (NIAID)